Trial Profile
PaIonosetron + Aprepitant + Dexamethasone for moderately emetic chemotherapy induced nausea and voimiting Phase II study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2016
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Palonosetron (Primary) ; Granisetron; Ondansetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 01 Oct 2016 Status changed from recruiting to active, no longer recruiting, according to results published in the International Journal of Urology.
- 01 Apr 2013 Planned end date changed from 1 Apr 2013 to 1 Mar 2014 as reported by University Hospital Medical Information Network - Japan.
- 13 Jun 2012 New trial record